A prospective head-to-head comparison of [68Ga]Ga-P16-093 and [68Ga]Ga-PSMA-11 PET/CT in patients with primary prostate cancer-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

A prospective head-to-head comparison of [68Ga]Ga-P16-093 and [68Ga]Ga-PSMA-11 PET/CT in patients with primary prostate cancer

Published:2023-05-26 Issue:10 Volume:50 Page:3126-3136
ISSN:1619-7070
Container-title:European Journal of Nuclear Medicine and Molecular Imaging
language:en
Short-container-title:Eur J Nucl Med Mol Imaging

Author:

Wang Guochang,Li Linlin,Zhu Ming,Zang Jie,Wang Jiarou,Wang Rongxi,Yan Weigang,Zhu Lin,Kung Hank F.,Zhu Zhaohui

Funder

the National High Level Hospital Clinical Research Funding

the Fundamental Research Funds for the Central Universities

Chinese Academy of Medical Science Innovation Fund for Medical Sciences

Beijing Natural Science Foundation

the National Natural Science Foundation of China

Publisher

Springer Science and Business Media LLC

Subject

Radiology, Nuclear Medicine and imaging,General Medicine,Radiology, Nuclear Medicine and imaging,General Medicine

Link

https://link.springer.com/content/pdf/10.1007/s00259-023-06283-4.pdf

Reference31 articles.

1. Ghosh A, Heston WD. Tumor target prostate specific membrane antigen (PSMA) and its regulation in prostate cancer. J Cell Biochem. 2004;91:528–39. https://doi.org/10.1002/jcb.10661.

2. Masters SC, Hofling AA, Gorovets A, Marzella L. FDA approves Ga 68 PSMA-11 for prostate cancer imaging. Int J Radiat Oncol Biol Phys. 2021;111:27–8. https://doi.org/10.1016/j.ijrobp.2021.03.055.

3. Hofling AA, Fotenos AF, Niu G, Fallah J, Agrawal S, Wang SJ, et al. Prostate cancer theranostics: concurrent approvals by the Food and Drug Administration of the first diagnostic imaging drug indicated to select patients for a paired radioligand therapeutic drug. J Nucl Med. 2022;63:1642–3. https://doi.org/10.2967/jnumed.122.264299.

4. Hofman MS, Lawrentschuk N, Francis RJ, Tang C, Vela I, Thomas P, et al. Prostate-specific membrane antigen PET-CT in patients with high-risk prostate cancer before curative-intent surgery or radiotherapy (proPSMA): a prospective, randomised, multicentre study. Lancet. 2020;395:1208–16. https://doi.org/10.1016/S0140-6736(20)30314-7.

5. Perera M, Papa N, Christidis D, Wetherell D, Hofman MS, Murphy DG, et al. Sensitivity, specificity, and predictors of positive 68Ga-prostate-specific membrane antigen positron emission tomography in advanced prostate cancer: a systematic review and meta-analysis. Eur Urol. 2016;70:926–37. https://doi.org/10.1016/j.eururo.2016.06.021.

Cited by 8 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. “One Method to Label Them All”: A Single Fully Automated Protocol for GMP-Compliant ⁶⁸Ga Radiolabeling of PSMA-11, Transposable to PSMA-I&T and PSMA-617;Current Radiopharmaceuticals;2024-09

2. ⁶⁸Ga/¹⁷⁷Lu-Labeled Bivalent Agents for Targeting Hypoxia and PSMA-Binding in Prostate Cancer;Journal of Medicinal Chemistry;2024-07-29

3. Novel [⁶⁸Ga/¹⁷⁷Lu]Ga/Lu-AZ-093 as PSMA-Targeting Agent for Diagnosis and Radiotherapy;Molecular Pharmaceutics;2024-06-10

4. Diagnostic Performance of [¹⁸F]AlF-Thretide PET/CT in Patients with Newly Diagnosed Prostate Cancer Using Histopathology as Reference Standard;Journal of Nuclear Medicine;2024-05-09

5. Recent Progress in Synthesis of 99mTc-labeled Complexes with Nitroimidazoles as SPECT Probes for Targeting Tumor Hypoxia;Nuclear Medicine and Molecular Imaging;2024-04-25

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3